Table 5.

Among 5,120 postmenopausal women with a 5-year risk of hip fracture ≥ 1.5%, fracture incidence, hazard ratio, and 95% confidence interval of hip, clinical vertebral, wrist/forearm, and any clinical fracture associated with a 5-year increase in bisphosphonate use^a

Exposure	Subjects (No.)	Fractures		Adjusted HR (95% CI)c
		No.b	Incidence per 1,000 Person-years
	Hip Fracture
Bisphosphonate use (5 year increase)	4,912	127	9.0	1.33 (1.03–1.72)
	Wrist/Forearm Fracture
Bisphosphonate use (5 year increase)	3,943	159	14.3	1.14 (0.90–1.44)
	Clinical Vertebral Fracture
Bisphosphonate use (5 year increase)	4,759	235	17.4	1.21 (1.00–1.47)
	Any Clinical Fracture
Bisphosphonate use (5 year increase)	5,120	1,313	98.0	1.15 (1.07–1.25)

Abbreviations: CI, confidence interval; HR, hazard ratio.

^a5 years is equivalent to the interquartile range;

^bNumber of fractures during all follow-up years;

^cFollow-up period is from completion date of medication inventory to end of study in 2013–14. Estimates are from Cox proportional hazards models adjusted for age, race, education level, BMI, physical function score, general health rating, recreational physical activity, treated diabetes mellitus, severe memory impairment, glucocorticoid use ≥ 3 months, risk of hip fracture within 5 years calculated by WHI 11-item fracture risk algorithm, calcium supplement use, estrogen use during 6–10 years prior to medication inventory, parental hip fracture, smoking status, Parkinson’s disease diagnosis, alcohol ≥ 3 servings/day, and rheumatoid arthritis diagnosis and stratified by history of fracture after age 54.